➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Mallinckrodt
Medtronic
Dow
Johnson and Johnson

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for GWP42003-P


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug GWP42003-P?

GWP42003-P is an investigational drug.

There have been 25 clinical trials for GWP42003-P. The most recent clinical trial was a Phase 3 trial, which was initiated on December 9th 2019.

The most common disease conditions in clinical trials are Syndrome, Epilepsy, and Seizures. The leading clinical trial sponsors are GW Research Ltd, Augusta University, and State of Georgia.

There are eight hundred and two US patents protecting this investigational drug and four international patents.

Recent Clinical Trials for GWP42003-P
TitleSponsorPhase
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic TreatmentGW Research LtdPhase 2
An Open-label Extension Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett SyndromeGW Research LtdPhase 3
Investigation of Cognitive Outcomes With Cannabidiol Oral SolutionGW Research LtdPhase 4

See all GWP42003-P clinical trials

Clinical Trial Summary for GWP42003-P

Top disease conditions for GWP42003-P
Top clinical trial sponsors for GWP42003-P

See all GWP42003-P clinical trials

US Patents for GWP42003-P

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GWP42003-P   Start Trial Pharmaceutical formulations GW Pharma Limited (Cambridge, GB)   Start Trial
GWP42003-P   Start Trial Compositions and methods for treating chronic inflammation and inflammatory diseases Infirst Healthcare Limited (London, GB)   Start Trial
GWP42003-P   Start Trial Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols KANNALIFE SCIENCES, INC. (Huntington, NY)   Start Trial
GWP42003-P   Start Trial METAP2 inhibitors and methods of treating obesity SynDevRx, Inc. (Cambridge, MA)   Start Trial
GWP42003-P   Start Trial Compositions, uses and methods for making them   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GWP42003-P

Drugname Country Document Number Estimated Expiration Related US Patent
GWP42003-P Australia 2002231970 2021-02-14   Start Trial
GWP42003-P Canada 2438097 2021-02-14   Start Trial
GWP42003-P Canada 2533400 2021-02-14   Start Trial
GWP42003-P China 1886117 2021-02-14   Start Trial
GWP42003-P Cyprus 1115072 2021-02-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Baxter
Moodys
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.